Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

CALGARY, June 1 /PRNewswire-FirstCall/ – Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung were presented May 30, 2009 at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting is being held in Orlando, Florida from May 29 to June 2, 2009. The presentation, entitled “A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung” was delivered by Dr. Monica Mita, the study principal investigator at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas. The interim results demonstrate that the treatment has been well tolerated, with 15 of 36, or 42% of evaluable patients experiencing stable disease (SD) for more than 16 weeks, including five patients who have had SD for more than 24 weeks. One patient had SD for more than 80 weeks. Oncolytics reported on May 12, 2009, that full enrolment of 52 patients was completed, at which time nine patients were continuing on study. “The ASCO data are very encouraging, both in terms of efficacy in patients with sarcoma, and in those with other tumor histologies in whom the IDD group are investigating various REOLYSIN regimens,” said Dr. Frank Giles, Director, IDD, and Deputy Director, CTRC at UTHSCSA. Additional REOLYSIN results presented Two additional poster presentations covering positive results of REOLYSIN trials were also presented at the ASCO meeting on May 30, 2009. Dr. Johann de Bono and colleagues delivered a poster presentation entitled “A Phase I Study of the Combination of Intravenous Reolysin (REO) and Gemcitabine (GEM) in Patients (pts) with Advanced Cancer.” The results, which were previously announced in March 2009, demonstrated that the combination of REOLYSIN and gemcitabine was well tolerated, and resulted in disease control for a majority of the patients. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and/or clinical responses and five patients had SD for 4-8 cycles, for a total disease control rate (CR (Complete Response)+PR+SD) of 70%. Dr. Sanjay Goel and colleagues delivered a poster entitled “Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced Solid Tumors.” The results, which were previously announced in June 2007, demonstrated that REOLYSIN was well tolerated. Of 18 patients treated in the trial, eight demonstrated SD or better as measured by Response Evaluation Criteria in Solid Tumors (RECIST) including a patient with progressive breast cancer who experienced a PR (34% shrinkage in tumor volume). All three posters will be available today on the Oncolytics website at www.ir.oncolyticsbiotech.com About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.ir.oncolyticsbiotech.com This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN, the Company’s expectations related to the results of trials investigating delivery of REOLYSIN, and the Company’s belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws. SOURCE Oncolytics Biotech Inc. Released June 1, 2009 View All Press Releases 4350 Executive Drive Suite 325 San Diego, CA 92121 [email protected] Company Our Mission Leadership Board of Directors Careers Contact Science Our Science Pipeline Resources Investors Overview News Events Stock Information Filings Corporate Governance FAQs Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent Copyright © 2026 Oncolytics Biotech Inc. {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/lsc-wp-theme-main/*","/wp-content/themes/astra/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} <div class="wcc-consent-container wcc-hide" role="complementary"> <div class="wcc-consent-bar" data-tag="notice" style="background-color:#FFFFFF;border-color:#f4f4f4"> <div class="wcc-notice"> <p id="wcc-title" class="wcc-title" data-tag="title" role="heading" aria-level="1" aria-labelledby="wcc-title" style="color:#212121"></p><div class="wcc-notice-group"> <div id="wcc-notice-des" class="wcc-notice-des" data-tag="description" aria-describedby="wcc-notice-des" style="color:#212121"> <p>We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.</p> </div><div class="wcc-notice-btn-wrapper" data-tag="notice-buttons"> <button class="wcc-btn wcc-btn-customize" aria-label="Customize" data-tag="settings-button" style="color:#001958;background-color:transparent">Customize</button> <button class="wcc-btn wcc-btn-reject" aria-label="Reject All" data-tag="reject-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0">Reject All</button> <button class="wcc-btn wcc-btn-accept" aria-label="Accept All" data-tag="accept-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0">Accept All</button> </div></div></div></div></div><div class="wcc-modal" role="dialog" aria-label="Privacy Overview"> <div class="wcc-preference-center" data-tag="detail" style="color:#212121;background-color:#FFFFFF;border-color:#f4f4f4"> <div class="wcc-preference-header"> <span id="wcc-preference-title" class="wcc-preference-title" data-tag="detail-title" role="heading" aria-level="1" aria-labelledby="wcc-preference-title" style="color:#212121">Privacy Overview</span> <button class="wcc-btn-close" aria-label="Close cookie preference modal" data-tag="detail-close"> <img src="https://ir.oncolyticsbiotech.com/wp-content/plugins/webtoffee-cookie-consent/lite/frontend/images/close.svg" alt="Close"> </button> </div><div class="wcc-preference-body-wrapper"> <div class="wcc-preference-content-wrapper" data-tag="detail-description" style="color:#212121"> <p>This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.</p> </div> <div class="wcc-google-privacy-policy" data-tag="google-privacy-policy"> </div><div class="wcc-accordion-wrapper" data-tag="detail-categories"> <div class="wcc-accordion" id="wccDetailCategorynecessary" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Necessary" data-tag="detail-category-title" style="color:#212121">Necessary</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchnecessary"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>wt_consent</div></li><li><div>Duration</div><div>1 year</div></li><li><div>Description</div><div>Used for remembering users’ consent preferences to be respected on subsequent site visits. It does not collect or store personal information about visitors to the site.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_cfuvid</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>Cloudflare sets this cookie to track users across sessions to optimize user experience by maintaining session consistency and providing personalized services</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>rc::a</div></li><li><div>Duration</div><div>never</div></li><li><div>Description</div><div>This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>rc::c</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>__cf_bm</div></li><li><div>Duration</div><div>1 hour</div></li><li><div>Description</div><div>This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. </div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryanalytics" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Analytics" data-tag="detail-category-title" style="color:#212121">Analytics</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchanalytics"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_ga</div></li><li><div>Duration</div><div>1 year 1 month 4 days</div></li><li><div>Description</div><div>Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_gid</div></li><li><div>Duration</div><div>1 day</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store information on how visitors use a website while also creating an analytics report of the website's performance. Some of the collected data includes the number of visitors, their source, and the pages they visit anonymously.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_gat_gtag_UA_*</div></li><li><div>Duration</div><div>1 minute</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store a unique user ID.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_ga_*</div></li><li><div>Duration</div><div>1 year 1 month 4 days</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store and count page views.</div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryperformance" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Performance" data-tag="detail-category-title" style="color:#212121">Performance</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchperformance"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>INGRESSCOOKIE</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>This cookie is used for load balancing and session stickiness. This technical session identifier is required for some website features. </div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryadvertisement" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Advertisement" data-tag="detail-category-title" style="color:#212121">Advertisement</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchadvertisement"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>c</div></li><li><div>Duration</div><div>6 months 2 days</div></li><li><div>Description</div><div>Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.</div></li></ul></div> </div> </div> </div></div><div class="wcc-footer-wrapper"> <span class="wcc-footer-shadow"></span> <div class="wcc-prefrence-btn-wrapper" data-tag="detail-buttons"> <button class="wcc-btn wcc-btn-reject" aria-label="Reject All" data-tag="detail-reject-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0"> Reject All </button> <button class="wcc-btn wcc-btn-preferences" aria-label="Save My Preferences" data-tag="detail-save-button" style="color:#FFFFFF;background-color:#E8614D;border-color:#E8614D"> Save My Preferences </button> <button class="wcc-btn wcc-btn-accept" aria-label="Accept All" data-tag="detail-accept-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0"> Accept All </button> </div><div style="padding: 8px 24px;font-size: 12px;font-weight: 400;line-height: 20px;text-align: right;border-radius: 0 0 6px 6px;direction: ltr;justify-content: flex-end;align-items: center;background-color:#EDEDED;color:#293C5B" data-tag="detail-powered-by"> Powered by <a target="_blank" rel="noopener" href="https://www.webtoffee.com/product/gdpr-cookie-consent" style="margin-left: 5px;line-height: 0"><img src="https://ir.oncolyticsbiotech.com/wp-content/plugins/webtoffee-cookie-consent/lite/frontend/images/webtoffee.svg" alt="Webtoffee logo" style="width: 78px;height: 13px;margin: 0"></a> </div></div></div></div><div class="wcc-overlay wcc-hide"></div> Secret Link ( () => { const lazyloadRunObserver = () => { const lazyloadBackgrounds = document.querySelectorAll( `.e-con.e-parent:not(.e-lazyloaded)` ); const lazyloadBackgroundObserver = new IntersectionObserver( ( entries ) => { entries.forEach( ( entry ) => { if ( entry.isIntersecting ) { let lazyloadBackground = entry.target; if( lazyloadBackground ) { lazyloadBackground.classList.add( 'e-lazyloaded' ); } lazyloadBackgroundObserver.unobserve( entry.target ); } }); }, { rootMargin: '200px 0px 200px 0px' } ); lazyloadBackgrounds.forEach( ( lazyloadBackground ) => { lazyloadBackgroundObserver.observe( lazyloadBackground ); } ); }; const events = [ 'DOMContentLoaded', 'elementor/lazyload/observe', ]; events.forEach( ( event ) => { document.addEventListener( event, lazyloadRunObserver ); } ); } )(); var astra = {"break_point":"1024","isRtl":"","is_scroll_to_id":"","is_scroll_to_top":"","is_header_footer_builder_active":"1","responsive_cart_click":"flyout","is_dark_palette":""}; //# sourceURL=astra-theme-js-js-extra jQuery.uiBackCompat = true; //# sourceURL=jquery-ui-core-js-before jQuery(function(jQuery){jQuery.datepicker.setDefaults({"closeText":"Close","currentText":"Today","monthNames":["January","February","March","April","May","June","July","August","September","October","November","December"],"monthNamesShort":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"nextText":"Next","prevText":"Previous","dayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"dayNamesShort":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"dayNamesMin":["S","M","T","W","T","F","S"],"dateFormat":"MM d, yy","firstDay":1,"isRTL":false});}); //# sourceURL=jquery-ui-datepicker-js-after var astraAddon = {"is_elementor_active":"1","sticky_active":"1","svgIconClose":"\u003Cspan class=\"ast-icon icon-close\"\u003E\u003Csvg viewbox=\"0 0 512 512\" aria-hidden=\"true\" role=\"img\" version=\"1.1\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" width=\"18px\" height=\"18px\"\u003E\n \u003Cpath d=\"M71.029 71.029c9.373-9.372 24.569-9.372 33.942 0L256 222.059l151.029-151.03c9.373-9.372 24.569-9.372 33.942 0 9.372 9.373 9.372 24.569 0 33.942L289.941 256l151.03 151.029c9.372 9.373 9.372 24.569 0 33.942-9.373 9.372-24.569 9.372-33.942 0L256 289.941l-151.029 151.03c-9.373 9.372-24.569 9.372-33.942 0-9.372-9.373-9.372-24.569 0-33.942L222.059 256 71.029 104.971c-9.372-9.373-9.372-24.569 0-33.942z\" /\u003E\n \u003C/svg\u003E\u003C/span\u003E","hf_account_show_menu_on":"hover","hf_account_action_type":"link","hf_account_logout_action":"link","header_main_stick":"1","header_above_stick":"0","header_below_stick":"0","stick_header_meta":"","header_main_stick_meta":"","header_above_stick_meta":"","header_below_stick_meta":"","sticky_header_on_devices":"desktop","sticky_header_style":"none","sticky_hide_on_scroll":"1","break_point":"1024","tablet_break_point":"1024","mobile_break_point":"767","header_main_shrink":"","header_animation_effect":"none","header_logo_width":"","responsive_header_logo_width":{"desktop":180,"tablet":"","mobile":"","desktop-svg-height":42},"stick_origin_position":"","site_layout":"","site_content_width":"1680","site_layout_padded_width":"1200","site_layout_box_width":"1200","header_builder_active":"1","component_limit":"10","is_header_builder_active":"1"}; //# sourceURL=astra-addon-js-js-extra var elementorFrontendConfig = {"environmentMode":{"edit":false,"wpPreview":false,"isScriptDebug":false},"i18n":{"shareOnFacebook":"Share on Facebook","shareOnX":"Share on X","pinIt":"Pin it","download":"Download","downloadImage":"Download image","fullscreen":"Fullscreen","zoom":"Zoom","share":"Share","playVideo":"Play Video","previous":"Previous","next":"Next","close":"Close","a11yCarouselPrevSlideMessage":"Previous slide","a11yCarouselNextSlideMessage":"Next slide","a11yCarouselFirstSlideMessage":"This is the first slide","a11yCarouselLastSlideMessage":"This is the last slide","a11yCarouselPaginationBulletMessage":"Go to slide"},"is_rtl":false,"breakpoints":{"xs":0,"sm":480,"md":521,"lg":1025,"xl":1440,"xxl":1600},"responsive":{"breakpoints":{"mobile":{"label":"Mobile Portrait","value":520,"default_value":767,"direction":"max","is_enabled":true},"mobile_extra":{"label":"Mobile Landscape","value":880,"default_value":880,"direction":"max","is_enabled":false},"tablet":{"label":"Tablet Portrait","value":1024,"default_value":1024,"direction":"max","is_enabled":true},"tablet_extra":{"label":"Tablet Landscape","value":1200,"default_value":1200,"direction":"max","is_enabled":true},"laptop":{"label":"Laptop","value":1366,"default_value":1366,"direction":"max","is_enabled":true},"widescreen":{"label":"Widescreen","value":1901,"default_value":2400,"direction":"min","is_enabled":true}},"hasCustomBreakpoints":true},"version":"4.2.3","is_static":false,"experimentalFeatures":{"additional_custom_breakpoints":true,"container":true,"e_panel_promotions":true,"nested-elements":true,"global_classes_should_enforce_capabilities":true,"e_variables":true,"e_opt_in_v4_page":true,"e_components":true,"e_interactions":true,"e_widget_creation":true,"import-export-customization":true,"e_pro_atomic_form":true,"e_pro_collection_loop":true,"e_pro_variables":true,"e_pro_interactions":true},"urls":{"assets":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor\/assets\/","ajaxurl":"https:\/\/ir.oncolyticsbiotech.com\/wp-admin\/admin-ajax.php","uploadUrl":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/uploads"},"nonces":{"floatingButtonsClickTracking":"3b1c5706b7","atomicFormsSendForm":"b73be6a22b"},"swiperClass":"swiper","settings":{"page":[],"editorPreferences":[]},"kit":{"active_breakpoints":["viewport_mobile","viewport_tablet","viewport_tablet_extra","viewport_laptop","viewport_widescreen"],"viewport_widescreen":1901,"viewport_mobile":520,"global_image_lightbox":"yes","lightbox_enable_counter":"yes","lightbox_enable_fullscreen":"yes","lightbox_enable_zoom":"yes","lightbox_enable_share":"yes","lightbox_title_src":"title","lightbox_description_src":"description"},"post":{"id":560,"title":"Oncolytics%20Biotech%28R%29%20Inc.%20Collaborators%20Present%20Positive%20Phase%20II%20Sarcoma%20Trial%20Results%20at%20ASCO%20Annual%20Meeting%20%7C%20Oncolytics%20Biotech%20Inc.","excerpt":"","featuredImage":false}}; //# sourceURL=elementor-frontend-js-before wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); //# sourceURL=wp-i18n-js-after var ElementorProFrontendConfig = {"ajaxurl":"https:\/\/ir.oncolyticsbiotech.com\/wp-admin\/admin-ajax.php","nonce":"60819fe108","urls":{"assets":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor-pro\/assets\/","rest":"https:\/\/ir.oncolyticsbiotech.com\/wp-json\/"},"settings":{"lazy_load_background_images":true},"popup":{"hasPopUps":false},"shareButtonsNetworks":{"facebook":{"title":"Facebook","has_counter":true},"twitter":{"title":"Twitter"},"linkedin":{"title":"LinkedIn","has_counter":true},"pinterest":{"title":"Pinterest","has_counter":true},"reddit":{"title":"Reddit","has_counter":true},"vk":{"title":"VK","has_counter":true},"odnoklassniki":{"title":"OK","has_counter":true},"tumblr":{"title":"Tumblr"},"digg":{"title":"Digg"},"skype":{"title":"Skype"},"stumbleupon":{"title":"StumbleUpon","has_counter":true},"mix":{"title":"Mix"},"telegram":{"title":"Telegram"},"pocket":{"title":"Pocket","has_counter":true},"xing":{"title":"XING","has_counter":true},"whatsapp":{"title":"WhatsApp"},"email":{"title":"Email"},"print":{"title":"Print"},"x-twitter":{"title":"X"},"threads":{"title":"Threads"}},"facebook_sdk":{"lang":"en_US","app_id":""},"lottie":{"defaultAnimationUrl":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor-pro\/modules\/lottie\/assets\/animations\/default.json"}}; //# sourceURL=elementor-pro-frontend-js-before /(trident|msie)/i.test(navigator.userAgent)&&document.getElementById&&window.addEventListener&&window.addEventListener("hashchange",function(){var t,e=location.hash.substring(1);/^[A-z0-9_-]+$/.test(e)&&(t=document.getElementById(e))&&(/^(?:a|select|input|button|textarea)$/i.test(t.tagName)||(t.tabIndex=-1),t.focus())},!1);

The release as fetched from its publisher. oncolyticsbiotech.com ↗